423 related articles for article (PubMed ID: 34019945)
1. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity.
Hassett KJ; Higgins J; Woods A; Levy B; Xia Y; Hsiao CJ; Acosta E; Almarsson Ö; Moore MJ; Brito LA
J Control Release; 2021 Jul; 335():237-246. PubMed ID: 34019945
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
3. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
4. Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size.
Shi R; Liu X; Wang Y; Pan M; Wang S; Shi L; Ni B
Hum Vaccin Immunother; 2024 Dec; 20(1):2342592. PubMed ID: 38714327
[TBL] [Abstract][Full Text] [Related]
5. Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery.
Da Silva Sanchez AJ; Zhao K; Huayamares SG; Hatit MZC; Lokugamage MP; Loughrey D; Dobrowolski C; Wang S; Kim H; Paunovska K; Kuzminich Y; Dahlman JE
J Control Release; 2023 Jan; 353():270-277. PubMed ID: 36423872
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanoparticle-based mRNA candidates elicit potent T cell responses.
Zeng Y; Escalona-Rayo O; Knol R; Kros A; Slütter B
Biomater Sci; 2023 Jan; 11(3):964-974. PubMed ID: 36537916
[TBL] [Abstract][Full Text] [Related]
7. Effect of lipid composition on RNA-Lipid nanoparticle properties and their sensitivity to thin-film freezing and drying.
AboulFotouh K; Southard B; Dao HM; Xu H; Moon C; Williams Iii RO; Cui Z
Int J Pharm; 2024 Jan; 650():123688. PubMed ID: 38070660
[TBL] [Abstract][Full Text] [Related]
8. Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA.
Miao H; Huang K; Li Y; Li R; Zhou X; Shi J; Tong Z; Sun Z; Yu A
Int J Pharm; 2023 Jun; 640():123050. PubMed ID: 37201764
[TBL] [Abstract][Full Text] [Related]
9. Lipid Microparticles Show Similar Efficacy With Lipid Nanoparticles in Delivering mRNA and Preventing Cancer.
Ji A; Xu M; Pan Y; Diao L; Ma L; Qian L; Cheng J; Liu M
Pharm Res; 2023 Jan; 40(1):265-279. PubMed ID: 36451070
[TBL] [Abstract][Full Text] [Related]
10. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
[TBL] [Abstract][Full Text] [Related]
11. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection.
Takanashi A; Pouton CW; Al-Wassiti H
Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979
[TBL] [Abstract][Full Text] [Related]
12. Polydispersity characterization of lipid nanoparticles for siRNA delivery using multiple detection size-exclusion chromatography.
Zhang J; Haas RM; Leone AM
Anal Chem; 2012 Jul; 84(14):6088-96. PubMed ID: 22816783
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Lipid Nanoparticles for Delivery in Primates.
Lam K; Schreiner P; Leung A; Stainton P; Reid S; Yaworski E; Lutwyche P; Heyes J
Adv Mater; 2023 Jun; 35(26):e2211420. PubMed ID: 36972555
[TBL] [Abstract][Full Text] [Related]
14. The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice.
Zhang W; Pfeifle A; Lansdell C; Frahm G; Cecillon J; Tamming L; Gravel C; Gao J; Thulasi Raman SN; Wang L; Sauve S; Rosu-Myles M; Li X; Johnston MJW
Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896985
[TBL] [Abstract][Full Text] [Related]
15. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.
Schoenmaker L; Witzigmann D; Kulkarni JA; Verbeke R; Kersten G; Jiskoot W; Crommelin DJA
Int J Pharm; 2021 May; 601():120586. PubMed ID: 33839230
[TBL] [Abstract][Full Text] [Related]
16. Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance.
Zhang J; Pei Y; Zhang H; Wang L; Arrington L; Zhang Y; Glass A; Leone AM
Mol Pharm; 2013 Jan; 10(1):397-405. PubMed ID: 23210488
[TBL] [Abstract][Full Text] [Related]
17. A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety.
Bae SH; Yoo S; Lee J; Park HJ; Kwon SP; Jin H; Park SI; Lee YS; Bang YJ; Roh G; Lee S; Youn SB; Kim IW; Oh HR; El-Damasy AK; Keum G; Kim H; Youn H; Nam JH; Bang EK
Bioact Mater; 2024 Aug; 38():486-498. PubMed ID: 38779592
[TBL] [Abstract][Full Text] [Related]
18. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.
Cheng X; Lee RJ
Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):129-137. PubMed ID: 26900977
[TBL] [Abstract][Full Text] [Related]
19. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
20. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles.
Yanez Arteta M; Kjellman T; Bartesaghi S; Wallin S; Wu X; Kvist AJ; Dabkowska A; Székely N; Radulescu A; Bergenholtz J; Lindfors L
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3351-E3360. PubMed ID: 29588418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
